A selective and sensitive reversed-phase HPLC method was developed for the determination of the antidepressant paroxetine in plasma. The method is based on the purple chromogen formed by a displacement reaction of paroxetine with 7,7,8,8-tetracyanoquinodimethane (TCNQ) in acetonitrile at 80 degrees C for 20 minutes. For the assay, the drug was extracted from 1 mL of plasma with chloroform and, after sample alkalinization, derivatized with TCNQ; then the reaction mixture was directly injected into a C18 column. Desipramine was used as internal standard. The mobile phase was acetonitrile-water (70:30) at a flow-rate of 1.0 mL/min, and the derivatives were eluted at 13.1 and 15.5 minutes for paroxetine and desipramine, respectively, and detected at 567 nm. Calibration curve was found linear over the range of 20-400 ng/mL, and the detection limit was 2 ng/mL at a signal-to-noise ratio of 3/1. Recoveries determined for 3 concentrations range between 81.3% and 88.1%. Intraday and interday relative standard deviation values were found to be within 3.8%-13.5% and 8.2%-14.6%, respectively. With this developed method, a pharmacokinetic study was performed for paroxetine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/01.ftd.0000185768.36878.49 | DOI Listing |
BMC Med Inform Decis Mak
January 2025
Department of Health Administration and Policy, College of Public Health, George Mason University, 4400 University Dr, Fairfax, VA, 22030, USA.
Background: Antidepressants are a primary treatment for depression, yet prescribing them poses significant challenges due to the absence of clear guidelines for selecting the most suitable option for individual patients. This study aimed to analyze prescribing patterns for antidepressants across healthcare providers, including physicians, physician assistants, nurse practitioners, and pharmacists, to better understand the complex factors influencing these patterns in the management of depression.
Methods: Least Absolute Shrinkage and Selection Operator (LASSO) regression was employed to identify variables that explained the variation in the prescribed antidepressants, utilizing a large number of claims.
Clin Transl Sci
February 2025
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, University of Florida College of Pharmacy, Gainesville, Florida, USA.
Tramadol, the 41st most prescribed drug in the United States in 2021 is a prodrug activated by CYP2D6, which is highly polymorphic. Previous studies showed enzyme-inhibitor affinity varied between different CYP2D6 allelic variants with dextromethorphan and atomoxetine metabolism. However, no study has compared tramadol metabolism in different CYP2D6 alleles with different CYP2D6 inhibitors.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Fengxian Hospital, Southern Medical University, Shanghai, China.
Background: In the past few decades, selective serotonin reuptake inhibitors (SSRIs) became widely used antidepressants worldwide. Therefore, the adverse reactions of patients after SSRI administration became a public and clinical concern. In this study, we conducted a pharmacovigilance study using the Adverse Event Reporting System (FAERS) database of the US Food and Drug Administration.
View Article and Find Full Text PDFAntibiotics (Basel)
January 2025
Laboratory of Basic and Applied Bacteriology, Department of Microbiology, Center of Biological Sciences, Universidade Estadual de Londrina, Londrina 86057-970, Brazil.
Multidrug-resistant bacteria cause over 700,000 deaths annually, a figure projected to reach 10 million by 2050. Among these bacteria, the ESKAPEE group is notable for its multiple resistance mechanisms. Given the high costs of developing new antimicrobials and the rapid emergence of resistance, drug repositioning offers a promising alternative.
View Article and Find Full Text PDFCureus
December 2024
Ernest Mario School of Pharmacy, Rutgers University, Piscataway, USA.
Objective: Patients with major depressive disorder (MDD) often face poor health outcomes. Additionally, patients with multiple hospitalizations tend to have worse predicted disease prognosis. Antidepressant medications remain a first-line treatment option for MDD, but data evaluating the effects of different antidepressants on psychiatric readmission rates is lacking.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!